Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ: AVIR · Real-Time Price · USD
3.500
-0.010 (-0.28%)
Aug 13, 2025, 4:00 PM - Market closed
Atea Pharmaceuticals Employees
Atea Pharmaceuticals had 56 employees as of December 31, 2024. The number of employees decreased by 19 or -25.33% compared to the previous year.
Employees
56
Change (1Y)
-19
Growth (1Y)
-25.33%
Revenue / Employee
n/a
Profits / Employee
-$2,430,839
Market Cap
277.75M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56 | -19 | -25.33% |
Dec 31, 2023 | 75 | 5 | 7.14% |
Dec 31, 2022 | 70 | 11 | 18.64% |
Dec 31, 2021 | 59 | 20 | 51.28% |
Dec 31, 2020 | 39 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AVIR News
- 5 days ago - Atea Pharmaceuticals, Inc. (AVIR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 14 days ago - Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 - GlobeNewsWire
- 7 weeks ago - Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - GlobeNewsWire
- 3 months ago - Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - GlobeNewsWire
- 4 months ago - Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewsWire